U.S. markets closed
  • S&P 500

    -96.09 (-2.45%)
  • Dow 30

    -559.85 (-1.75%)
  • Nasdaq

    -478.54 (-3.52%)
  • Russell 2000

    -84.21 (-3.69%)
  • Crude Oil

    -0.07 (-0.11%)
  • Gold

    -5.10 (-0.29%)
  • Silver

    -0.08 (-0.31%)

    -0.0006 (-0.05%)
  • 10-Yr Bond

    +0.1290 (+9.29%)

    -0.0135 (-0.95%)

    +0.5020 (+0.47%)

    -1,496.79 (-3.06%)
  • CMC Crypto 200

    -27.36 (-2.75%)
  • FTSE 100

    -7.01 (-0.11%)
  • Nikkei 225

    +496.57 (+1.67%)

Johnson & Johnson Shares Pop on Stronger-Than-Expected 4th-Quarter Results

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

- By Mayank Marwah

Johnson & Johnson (NYSE:JNJ) released its fourth-quarter fiscal 2020 results before the opening bell on Jan. 26. The world's biggest maker of consumer health care products posted an earnings and revenue beat and provided a strong outlook for the full-year 2021.

By the numbers

The New Brunswick, New Jersey-based company recorded adjusted earnings per share of $1.86 in the quarter, down 1.1% year over year. Revenue of $22.48 billion gained 8.3% year over year. Analysts had predicted EPS of $1.82 on $21.67 billion in revenue.

CEO Alex Gorsky said the following:

"Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic, I'm incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-based healthcare company, enabled us to lead in the fight against COVID-19. We continue to progress our COVID-19 vaccine candidate and look forward to sharing details from our Phase 3 study soon. Johnson & Johnson was built for times like these, and I am extremely confident in our ability to deliver lasting value and continued innovation in 2021 and for years to come."

Shares of the stock surged 0.83% to $167.40 in pre-market trading following the earnings release.

Segment performance

Operational sales of consumer health care products, excluding the impact of acquisitions and divestitures, rose 2% for the fourth quarter to $3.6 billion. The growth was primarily driven by strong sales of skin health and beauty care products. Additionally, robust sales of over-the-counter products such as Tylenol analgesics, digestive health care products and Listerine mouthwash contributed to the segment's quarterly growth.

The pharmaceutical unit, which accounts for more than 50% of the company's revenue, witnessed operational sales growth of 14.6% year over year to $12.26 billion, without considering the impact of acquisitions and divestitures. The company attributed the growth to strong sales of anti-inflammatory treatment Stelara as well as Imbruvica.

Medical device operational sales, barring the acquisitions and divestitures, declined 2.2% to $6.58 billion as the coronavirus outbreak compelled hospitals to defer elective surgeries. This, however, reflects a recovery from a 3.3% sales decline reported in the third quarter.


The company has issued full year 2021 guidance. Adjusted EPS is projected to be in the range of $9.40 to $9.60. Operational revenue is expected to be around $88.8 billion to $90 billion.

Disclosure: I do not hold any positions in the stocks mentioned.

Read more here:

Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.